2024
Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting
Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Sprenkle P, Ross A. Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting. European Urology Oncology 2024 PMID: 39098389, DOI: 10.1016/j.euo.2024.07.010.Peer-Reviewed Original ResearchDecipher genomic classifierRisk of metastasisBiochemical recurrenceRadical prostatectomyGenomic classifierDecipher testProstate cancerProstate Risk Assessment Postsurgical ScoreRisk of biochemical recurrencePatient's prostate cancerRisk of cancer recurrencePathological risk factorsProstate cancer outcomesCox proportional hazards regressionRetrospective cohort studyElectronic health record dataReal-world settingsProportional hazards regressionHealth record dataReal-world practice settingsProstate biopsyRP specimensOncological outcomesPrognostic significanceMedian age
2021
Targeting prostate cancer with Clostridium perfringens enterotoxin functionalized nanoparticles co-encapsulating imaging cargo enhances magnetic resonance imaging specificity
Martin DT, Lee JS, Liu Q, Galiana G, Sprenkle PC, Humphrey PA, Petrylak DP, Weinreb JC, Schulam PG, Weiss RM, Fahmy TM. Targeting prostate cancer with Clostridium perfringens enterotoxin functionalized nanoparticles co-encapsulating imaging cargo enhances magnetic resonance imaging specificity. Nanomedicine Nanotechnology Biology And Medicine 2021, 40: 102477. PMID: 34740868, DOI: 10.1016/j.nano.2021.102477.Peer-Reviewed Original ResearchConceptsFunctionalized nanoparticlesProstate cancerTumor specificityNanoparticlesHuman prostate cancer biopsiesTumor-bearing mouse modelClaudin-3Average diameterLiver signal intensityProstate cancer biopsiesKey imaging toolContrast-enhanced MRIImaging specificityClostridium perfringens enterotoxinPotential clinical applicabilityDetection toolsMouse modelTumor localizationCancer biopsiesCancer specificityCldn-3Perfringens enterotoxinClinical applicabilityHigh expressionHigh gradeKnocking down claudin receptors leads to a decrease in prostate cancer cell migration, cell growth, cell viability and clonogenic cell survival
Liu Q, Shen H, Naguib A, Weiss RM, Martin DT. Knocking down claudin receptors leads to a decrease in prostate cancer cell migration, cell growth, cell viability and clonogenic cell survival. Molecular Biomedicine 2021, 2: 31. PMID: 35006480, PMCID: PMC8607359, DOI: 10.1186/s43556-021-00053-0.Peer-Reviewed Original ResearchProstate cancer cell growthCancer cell growthProstate cancer cellsProstate cancerLNCaP cellsCommon solid organ malignancyHuman prostate cancer specimensProstate cancer cell migrationSolid organ malignanciesAdvanced prostate cancerCancer cellsHuman prostate cancer cellsNormal human prostate cellsMetastatic human prostate cancer cellsProstate cancer specimensHuman prostate cellsCell growthNew molecular targetsCell viabilityCell migrationCancer cell migrationClaudin receptorsOrgan malignanciesProstate cancer PC3Clonogenic cell survivalThe Prognostic Association of Prostate MRI PI-RADS™ v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis
Rajwa P, Mori K, Huebner NA, Martin DT, Sprenkle PC, Weinreb JC, Ploussard G, Pradere B, Shariat SF, Leapman MS. The Prognostic Association of Prostate MRI PI-RADS™ v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. Journal Of Urology 2021, 206: 507-516. PMID: 33904755, DOI: 10.1097/ju.0000000000001821.Peer-Reviewed Original ResearchConceptsRisk of BCRPI-RADS v2 scoreDefinitive local therapyBiochemical recurrencePrognostic significanceRadical prostatectomyProstate cancerV2 scoreLocal therapySystematic reviewMagnetic resonance imaging (MRI) classificationPrimary definitive treatmentIndependent prognostic significanceRisk of biasSignificant prostate cancerProstate Imaging ReportingPI-RADS v2Prostate cancer diagnosisWeb of ScienceReliable diagnostic toolOncologic outcomesDefinitive treatmentMRI findingsPI-RADSPrognostic associationDoubling of Decipher Biopsy Genomic Score Is Related to Disease Reclassification on Subsequent Surveillance Biopsy but Not Adverse Features on Radical Prostatectomy
Ghabili K, Paulson N, Syed JS, Nawaf CB, Khajir G, Martin DT, Onofrey J, Leapman MS, Levi A, Weinreb JC, Humphrey PA, Sprenkle PC. Doubling of Decipher Biopsy Genomic Score Is Related to Disease Reclassification on Subsequent Surveillance Biopsy but Not Adverse Features on Radical Prostatectomy. Case Reports In Urology 2021, 2021: 2687416. PMID: 33936831, PMCID: PMC8054861, DOI: 10.1155/2021/2687416.Peer-Reviewed Original ResearchBiopsy scoreRadical prostatectomyActive surveillanceBiopsy Gleason grade groupGleason grade group 2Gleason grade group 4Low-risk prostate cancerActive surveillance populationGrade group 4Subsequent surveillance biopsiesOrgan-confined diseaseGrade group 2Gleason grade groupLow-risk categoryBiopsy reclassificationDisease reclassificationSurveillance biopsiesFinal pathologyThird biopsySecond biopsySurveillance populationProstate cancerAdverse featuresGroup 2Genomic score